>...
数据说明

1. 本数据库收录了主流期刊的医药学相关文献,并关联了文献的主题药物。
2. 支持主题药物、期刊名称、卷、期、文献标题及doi等多维度检索。

关闭
文献信息列表 药渡-医药研发领域大数据信息平台首页
文献筛选
更新日期:2018-11-28
  • 期刊名称
  • 开始页码
  • 发表年份
  • 靶点
  • 文献标题
  • DOI号
  • 适应症
  • 作者
  • 主题药物
其他选项:
中国CDE注册与受理 NDA ANDA BLA 发表年份 文献标题 上一页 下一页
首页 上一页 1 2 下一页 末页 GO

    Absorption, distribution, metabolism and elimination of 14C-ETX0914, a novel inhibitor of bacterial type-II topoisomerases in rodents

    作者:Vishwanathan, K.

  • 出版源: Xenobiotica, 2017, 47 (1): 31.

    主题药物: Zoliflodacin

    In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor

    作者:Yamaguchi, J. I.

  • 出版源: Xenobiotica, 2017, 47 (4): 314.

    主题药物: Luseogliflozin Hydrate

    Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials

    作者:Mannucci, E.

  • 出版源: Acta Diabetol, 2017, 54 (1): 19.

    主题药物: Dapagliflozin Propanediol Monohydrate

    Clinical pharmacokinetics of panobinostat, a novel histone deacetylase (HDAC) inhibitor: review and perspectives

    作者:Srinivas, N. R.

  • 出版源: Xenobiotica, 2017, 47 (4): 354.

    主题药物: Panobinostat Lactate

    In vitro characterization of belinostat glucuronidation: demonstration of both UGT1A1 and UGT2B7 as the main contributing isozymes

    作者:Wu, B.

  • 出版源: Xenobiotica, 2017, 47 (4): 277.

    主题药物: Belinostat

    The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC

    作者:Vokes, E.

  • 出版源: J Thorac Oncol, 2017, 12 (2): 194.

    主题药物: Ramucirumab

    Chemotherapy for advanced gastric cancer: future perspective in Japan

    作者:Shitara, K.

  • 出版源: Gastric Cancer, 2017, 20 (Suppl 1): 102.

    主题药物: Ramucirumab

    Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation

    作者:Engert, A.

  • 出版源: Leuk Lymphoma, 2017, 58 (1): 222.

    主题药物: Panobinostat Lactate

    A double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]-basimglurant and absolute bioavailability after oral administration and concomitant intravenous microdose administration of [13C6]-labeled basimglurant in humans

    作者:Mallalieu, N. L.

  • 出版源: Xenobiotica, 2017, 47 (2): 144.

    主题药物: Basimglurant Sulfate

    Effects of fingolimod administration in a genetic model of cognitive deficits

    作者:Lavin, A.

  • 出版源: J Neurosci Res, 2017, 95 (5): 1174.

    主题药物: Fingolimod Hydrochloride

    Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort

    作者:Giordano, S.

  • 出版源: Oncogene, 2017, 36 (9): 1200.

    主题药物: Crizotinib

    Fluorescence spectroscopic and molecular docking studies of the binding interaction between the new anaplastic lymphoma kinase inhibitor crizotinib and bovine serum albumin

    作者:Abdelhameed, Ali S.; Alanazi, Amer M.; Bakheit, Ahmed H.; Darwish, Hany W.; Ghabbour, Hazem A.; Darwish, Ibrahim A.

  • 出版源: Spectrochim. Acta, Part A, 2017, 171 : 174.

    主题药物: Crizotinib

    Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1

    作者:Tanaka, Y.

  • 出版源: J Gastroenterol, 2017, 52 (1): 94.

    主题药物: Simeprevir Sodium, Daclatasvir Dihydrochloride

    Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?

    作者:Malfait, A. M.

  • 出版源: Curr Opin Rheumatol, 2017, 29 (1): 110.

    主题药物: Tanezumab

    Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects

    作者:Phipps, A.

  • 出版源: Xenobiotica, 2017, 47 (3): 217.

    主题药物: Alectinib Hydrochloride

    Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab

    作者:Yoshizawa, T.

  • 出版源: Leuk Lymphoma, 2017, 58 (3): 699.

    主题药物: Obinutuzumab

    Increased FcgammaRIIB dominance contributes to the emergence of resistance to therapeutic antibodies in chronic lymphocytic leukaemia patients

    作者:Saunders, N. A.

  • 出版源: Oncogene, 2017, 36 (17): 2366.

    主题药物: Obinutuzumab

    FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study

    作者:Sehn, L.

  • 出版源: Leuk Lymphoma, 2017, 58 (2): 372.

    主题药物: Obinutuzumab

    Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis

    作者:Tsubouchi, H.

  • 出版源: J Gastroenterol, 2017, 52 (2): 229.

    主题药物: Tolvaptan

    Disposition and metabolism of TAK-438 (vonoprazan fumarate), a novel potassium-competitive acid blocker, in rats and dogs

    作者:Asahi, S.

  • 出版源: Xenobiotica, 2017, 47 (3): 255.

    主题药物: Vonoprazan Fumarate